Market Intelligence, Clinical Progress, and High-Purity Reagents for RB1 Pathway & Synthetic Lethality Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RB1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RB1 Recombinant Protein (Pocket Domain / Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RB1 Products |
| Gene Delivery | RB1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and knockdown constructs. |
View RB1 Products |
| Benchmark Ab | Anti-RB1 Recombinant Antibody Sequence-verified positive control for Western Blot and Flow Cytometry. |
View RB1 Products |
| Validator | RB1 siRNA Set For knockdown verification and specificity profiling. |
View RB1 Products |
| Related Target A | CDK4 Key upstream kinase phosphorylating RB1 to drive cell cycle entry. |
View CDK4 Products |
| Related Target B | CDK6 Co-driver of G1/S transition; major target in RB1-proficient cancers. |
View CDK6 Products |
| Related Target C | TP53 Co-mutated tumor suppressor; critical for dual-knockout synthetic lethality profiling. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Detection of RB1 phosphorylation status in CDK4/6 inhibitor screening | Sequence-verified recombinant RB1 domains expressed in Sf9 insect cells with native-like protein folding |
| High-throughput validation of RB1-deficient synthetic lethality | High-titer Lentivirus (shRNA/CRISPR) for stable RB1-knockout cell line construction |
| Lack of Controls | Recombinant benchmark antibodies and positive control lysates included |
| False Positives | Validated siRNA sets included for target specificity verification |
Live RB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Retinoblastoma 1 (RB1) pathway represents a cornerstone of modern oncology. Historically viewed as an "undruggable" tumor suppressor due to its intracellular localization and frequent loss-of-function mutations, the clinical focus has shifted from direct restoration to targeting synthetic lethal partners and downstream effectors. In RB1-proficient tumors (such as HR+/HER2- breast cancer), CDK4/6 inhibitors have revolutionized the standard of care by preventing RB1 phosphorylation and maintaining cell cycle arrest.
However, the emergence of acquired RB1 mutations or complete RB1 loss represents a primary resistance mechanism to CDK4/6 therapies. The next wave of oncology R&D is aggressively pursuing drug candidates that selectively target RB1-deficient cancers. These strategies exploit synthetic lethality by inhibiting cell cycle checkpoints (e.g., WEE1, PKMYT1, ATR) or spindle assembly components (e.g., Aurora Kinase A, KIF11), driving RB1-null cancer cells into catastrophic mitosis and apoptosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CDK4/6 Inhibitors | Pfizer, Eli Lilly, Novartis | HR+/HER2- Breast Cancer | Phosphorylation assays (Need high-purity recombinant RB1 target substrates) |
| Synthetic Lethal Small Molecules (ATR/WEE1/PKMYT1) | AstraZeneca, Repare Therapeutics | SCLC, Triple-Negative Breast Cancer, Prostate Cancer | Cell line construction (Need high-titer Lentivirus for stable RB1 knockout) |
| Gene Therapy / RNA Therapeutics | Academic institutions, Biotech startups | Retinoblastoma, RB1-deficient Solid Tumors | Expression validation (Need sequence-verified ORF clones and specific siRNAs) |